The $4.8 billion acquisition of Amicus Therapeutics by BioMarin is, on its surface, a familiar healthcare story: portfolio expansion, accelerated revenue Discover how BioMarin's acquisition impacts ...
The Wall Street Journal called the IPO the hottest of this year. No, it wasn’t a new artificial intelligence stock or social media site. It was for a company most people have never heard of, but that ...
Most industries relish the opportunity to have their day in the sun. When you’ve hit on something the world needs, the influx of attention and funds can be highly gratifying. Of course, sometimes that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback